iBio partners with AstralBio for a $15M private placement to develop obesity treatment antibodies.
iBio (IBIO) shares surged after entering into a collaboration agreement with AstralBio to discover, engineer, and develop antibodies to treat obesity and cardiometabolic conditions. iBio's AI-powered technology will be used to discover, engineer, and develop obesity-focused therapeutic targets. The company announced a $15M private placement financing to support new partnerships like this one with AstralBio.
March 27, 2024
7 Articles